Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31092601 | 0.98 | EPHX1 (0.54) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL1945087 | 0.95 | EPHX1 (0.54) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL7642789 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL21359023 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL4555669 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL18248508 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL1404164 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL8763769 | 0.93 | EPHX1 (0.53) | EPHX1POLBMMP9MMP8MMP13 | |
| SCHEMBL2183709 | 0.89 | EPHX1 (0.59) | EPHX1MMP9MMP8MMP13ALOX5 | |
| SCHEMBL1508070 | 0.87 | POLB (0.54) | POLBMMECNR2ALDH1A1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366837-A2 | COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION | The General Hospital Corporation (US) | 2024-05-15 | — | — | EP | claimed |
| WO-2023283554-A2 | COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-12 | — | — | WO | claimed |
| WO-2005007094-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK INC. (US) | 2005-01-27 | — | — | WO | claimed |
| CN-1404474-A | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-03-19 | — | — | CN | claimed |
| US-12409157-B2 | Mitofusin activators and methods of use thereof | DORN, GERALD W., II, DR. | 2025-09-09 | — | — | US | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | DORN, GERALD W., II, DR. | 2024-03-14 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116143844-A | Hydrophilic trimeric indenyl metal organic nickel octahedral cage and preparation method and application thereof | 江苏科技大学 | 2023-05-23 | — | — | CN | disclosed |
| EP-4058464-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| CN-1404474-A | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-03-19 | — | — | CN | disclosed |
| US-6353128-B1 | FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK. | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-0946495-A4 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0946495-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024756-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0274467-A1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM. | BLAIR GEHO W (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0274467-A4 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM. | BLAIR GEHO W (US) | 1988-06-16 | — | — | EP | disclosed |
| WO-1988000474-A1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | BLAIR GEHO W (US) | 1988-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082180-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885POLB 1519/4885MMP9 4514/4885 |
| US-11141390-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | EPHX1 4069/4885POLB 1519/4885MMP9 4514/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | EPHX1 3913/4885POLB 4018/4885MMP9 1186/4885 |
| US-20210251927-A1 | MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, FIS1, TFB2M | EPHX1 4069/4885POLB 1519/4885MMP9 4514/4885 |
| US-12409157-B2 | Mitofusin activators and methods of use thereof | MFN2, FIS1, TFB2M | EPHX1 4069/4885POLB 1519/4885MMP9 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.